-
1
-
-
0023812652
-
Clozapire for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
-
Kane J, Honigfeld G, Singer J, et al, and the Clozaril Collaborative Study Group. Clozapire for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
-
(1988)
Arch Gen Psychiatry
, vol.45
, pp. 789-796
-
-
Kane, J.1
Honigfeld, G.2
Singer, J.3
-
2
-
-
84910188503
-
-
Basel, Switzerland: Karger
-
Bobon DP, Janssen PAJ, Bobon D, eds. The Neuroleptics: Modern Problems of Pharmacopsychiatry, vol. 5. Basel, Switzerland: Karger; 1970
-
(1970)
The Neuroleptics: Modern Problems of Pharmacopsychiatry
, vol.5
-
-
Bobon, D.P.1
Janssen, P.A.J.2
Bobon, D.3
-
3
-
-
0013962408
-
Das Wirkungsprofil eines chemische neuartigen Breitbandneuroleptikums der Dibenzodiazepingruppe
-
Gross H, Langner E. Das Wirkungsprofil eines chemische neuartigen Breitbandneuroleptikums der Dibenzodiazepingruppe. Wien Med Wochenschr 1969;116:814-816
-
(1969)
Wien Med Wochenschr
, vol.116
, pp. 814-816
-
-
Gross, H.1
Langner, E.2
-
4
-
-
0009048853
-
Das klinische Wirkungsspektrum eines neuen Dibenzodiazepin-Derivats
-
Berzewski H, Helmchen H, Hippius H, et al. Das klinische Wirkungsspektrum eines neuen Dibenzodiazepin-Derivats. Arzneimittelforschung 1969;19: 495-496
-
(1969)
Arzneimittelforschung
, vol.19
, pp. 495-496
-
-
Berzewski, H.1
Helmchen, H.2
Hippius, H.3
-
6
-
-
0002447718
-
Ergebnisse eines Doppelblindversuchs von HF1854 im Vergleich zu Levomepromazin
-
Angst J, Jaenicke U, Padrutt A, et al. Ergebnisse eines Doppelblindversuchs von HF1854 im Vergleich zu Levomepromazin. Pharmakopsychiatrie 1971;4:192-200
-
(1971)
Pharmakopsychiatrie
, vol.4
, pp. 192-200
-
-
Angst, J.1
Jaenicke, U.2
Padrutt, A.3
-
7
-
-
0001427177
-
Kritische Stellungnahme zum Begriff der Neuroleptika (anhand von pharmakologischen und klinischen Befunden mit Clozapin)
-
Stille G, Hippius H. Kritische Stellungnahme zum Begriff der Neuroleptika (anhand von pharmakologischen und klinischen Befunden mit Clozapin). Pharmakopsychiatrie 1971;4:182-191
-
(1971)
Pharmakopsychiatrie
, vol.4
, pp. 182-191
-
-
Stille, G.1
Hippius, H.2
-
8
-
-
0017658058
-
Agranulocytosis in patients treated with clozapine: A study of the Finnish epidemic
-
Amsler HA, Teerenhovi L, Barth E, et al. Agranulocytosis in patients treated with clozapine: a study of the Finnish epidemic. Acta Psychiatr Scand 1977;56:241-248
-
(1977)
Acta Psychiatr Scand
, vol.56
, pp. 241-248
-
-
Amsler, H.A.1
Teerenhovi, L.2
Barth, E.3
-
9
-
-
0018565672
-
Clozapine, chlorpromazine, and placebo in newly hospitalized acutely schizophrenic patients: A controlled, double-blind comparison
-
Shopsin B, Klein H, Aaronsom M, et al. Clozapine, chlorpromazine, and placebo in newly hospitalized acutely schizophrenic patients: a controlled, double-blind comparison. Arch Gen Psychiatry 1979;36:657-664
-
(1979)
Arch Gen Psychiatry
, vol.36
, pp. 657-664
-
-
Shopsin, B.1
Klein, H.2
Aaronsom, M.3
-
11
-
-
0026772116
-
Clinical and biologic response to clozapine in patients with schizophrenia: Crossover comparison with fluphenazine
-
Pickar D, Owen RR, Litman RE, et al. Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992;49:345-353
-
(1992)
Arch Gen Psychiatry
, vol.49
, pp. 345-353
-
-
Pickar, D.1
Owen, R.R.2
Litman, R.E.3
-
12
-
-
0028355999
-
Clozapine effects on positive and negative symptoms: A six-month trial in treatment-refractory schizophrenics
-
Lindenmayer JP, Grochowski S, Mabugat L. Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. J Clin Psychopharmacol 1994;14:201-204
-
(1994)
J Clin Psychopharmacol
, vol.14
, pp. 201-204
-
-
Lindenmayer, J.P.1
Grochowski, S.2
Mabugat, L.3
-
13
-
-
0000052449
-
Efficacy of elozapine versus haloperidol in a long-term clinical trial
-
Kane JM, Schooler NR, Marder S, et al. Efficacy of elozapine versus haloperidol in a long-term clinical trial [abstract]. Schizophr Res 1996;18:127
-
(1996)
Schizophr Res
, vol.18
, pp. 127
-
-
Kane, J.M.1
Schooler, N.R.2
Marder, S.3
-
14
-
-
0031936086
-
The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics
-
Miller CH, Mohr F, Umbricht D, et al. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998;59:69-75
-
(1998)
J Clin Psychiatry
, vol.59
, pp. 69-75
-
-
Miller, C.H.1
Mohr, F.2
Umbricht, D.3
-
15
-
-
0028019245
-
Effects of clozapine on cognitive function in schizophrenia
-
Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 1994;55(9, suppl B):82-87
-
(1994)
J Clin Psychiatry
, vol.55
, Issue.9 SUPPL. B
, pp. 82-87
-
-
Lee, M.A.1
Thompson, P.A.2
Meltzer, H.Y.3
-
16
-
-
0024468417
-
Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypotheses of schizophrenia
-
Berl
-
Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypotheses of schizophrenia. Psychopharmacology (Berl) 1989;99:S18-S27
-
(1989)
Psychopharmacology
, vol.99
-
-
Meltzer, H.Y.1
-
17
-
-
0024989576
-
Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients
-
Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-897
-
(1990)
Hosp Community Psychiatry
, vol.41
, pp. 892-897
-
-
Meltzer, H.Y.1
Burnett, S.2
Bastani, B.3
-
18
-
-
0028869668
-
Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment
-
Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-190
-
(1995)
Am J Psychiatry
, vol.152
, pp. 183-190
-
-
Meltzer, H.Y.1
Okayli, G.2
-
19
-
-
0030778896
-
Mortality in current and former users of clozapine
-
Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997;8:671-677
-
(1997)
Epidemiology
, vol.8
, pp. 671-677
-
-
Walker, A.M.1
Lanza, L.L.2
Arellano, F.3
-
20
-
-
0031967082
-
Suicide in schizophrenia: Risk factors and clozapine treatment
-
Meltzer HY. Suicide in schizophrenia: risk factors and clozapine treatment. J Clin Psychiatry 1998;59(suppl 3):15-20
-
(1998)
J Clin Psychiatry
, vol.59
, Issue.3 SUPPL.
, pp. 15-20
-
-
Meltzer, H.Y.1
-
21
-
-
0029584660
-
Violence and schizophrenia: Clozapine as a specific antiaggressive agent
-
Buckley P, Bartell J, Donenwirth K, et al. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995;23:607-611
-
(1995)
Bull Am Acad Psychiatry Law
, vol.23
, pp. 607-611
-
-
Buckley, P.1
Bartell, J.2
Donenwirth, K.3
-
22
-
-
0031956951
-
Clozapine reduces violence and persistent aggression in schizophrenia
-
Glazer WM, Dickson RA. Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psychiatry 1998;59 (suppl 3):8-14
-
(1998)
J Clin Psychiatry
, vol.59
, Issue.3 SUPPL.
, pp. 8-14
-
-
Glazer, W.M.1
Dickson, R.A.2
-
23
-
-
0026517979
-
Dimensions of outcome with clozapine
-
Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry 1992:160(suppl 17):46-53
-
(1992)
Br J Psychiatry
, vol.160
, Issue.17 SUPPL.
, pp. 46-53
-
-
Meltzer, H.Y.1
-
24
-
-
0032978563
-
Clozapine: The commitment to patient safety
-
Alphs LD, Anand R. Clozapine: the commitment to patient safety. J Clin Psychiatry 1999;60(suppl 12):39-42
-
(1999)
J Clin Psychiatry
, vol.60
, Issue.12 SUPPL.
, pp. 39-42
-
-
Alphs, L.D.1
Anand, R.2
|